{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:12:20Z","timestamp":1793506340730,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)\/\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    , a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little data on outcome since the era of tyrosine kinase inhibitors. Among 5819 AML cases included in the DATAML registry, 20 patients with de novo\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    AML (0.3%) were identified. Eighteen patients treated with standard induction chemotherapy were analyzed in this study. Imatinib was added to chemotherapy in 16 patients. The female-to-male ratio was 1.25 and median age was 54 years. The t(9;22) translocation was the sole chromosomal abnormality in 12 patients. Main gene mutations detected by NGS were\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ,\n                    <jats:italic>RUNX1<\/jats:italic>\n                    and\n                    <jats:italic>NPM1<\/jats:italic>\n                    . Compared with patients with myeloid blast phase of chronic myeloid leukemia (CML-BP), de novo\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    AML had higher WBC, fewer additional chromosomal abnormalities, lower CD36 or CD7 expression and no\n                    <jats:italic>ABL1<\/jats:italic>\n                    mutations. Seventeen patients (94.4%) achieved complete remission (CR) or CR with incomplete hematologic recovery. Twelve patients were allografted in first remission. With a median follow-up of 6.3 years, the median OS was not reached and 2-year OS was 77% (95% CI: 50\u201391). Four out of five patients who were not transplanted did not relapse. Comparison of\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    AML, CML-BP, 2017 ELN intermediate (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009643) and adverse-risk patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009863) showed that patients with\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    AML had a significant better outcome than intermediate and adverse-risk patients.\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    AML patients treated with imatinib and intensive chemotherapy should not be included in the adverse-risk group of current AML classifications.\n                  <\/jats:p>","DOI":"10.1038\/s41408-024-01069-9","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T05:09:25Z","timestamp":1717132165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)\/BCR::ABL1. A DATAML registry study"],"prefix":"10.1038","volume":"14","author":[{"given":"Camille","family":"Gondran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-8377","authenticated-orcid":false,"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-0753","authenticated-orcid":false,"given":"Eric","family":"Delabesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Leguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Borel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-4404","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Vergez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-0064","authenticated-orcid":false,"given":"Jean-Philippe","family":"Vial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Baptiste","family":"Rieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-7938","authenticated-orcid":false,"given":"Nicolas","family":"Lechevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Luquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-3307","authenticated-orcid":false,"given":"Alban","family":"Canali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Charlotte","family":"de Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Largeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1069_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1069_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","volume":"95","author":"NR Neuendorff","year":"2016","unstructured":"Neuendorff NR, Burmeister T, D\u00f6rken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol. 2016;95:1211\u201321.","journal-title":"Ann Hematol"},{"key":"1069_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"1069_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/10428194.2012.701739","volume":"54","author":"S Konoplev","year":"2013","unstructured":"Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013;54:138\u201344.","journal-title":"Leuk Lymphoma"},{"key":"1069_CR6","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7:5122\u201331.","journal-title":"Blood Adv"},{"key":"1069_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/gcc.22936","volume":"60","author":"C Orsmark-Pietras","year":"2021","unstructured":"Orsmark-Pietras C, Landberg N, Lorenz F, Uggla B, H\u00f6glund M, Lehman S, et al. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study. Genes Chromosomes Cancer. 2021;60:426\u201333.","journal-title":"Genes Chromosomes Cancer"},{"key":"1069_CR8","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/leu.2017.86","volume":"31","author":"AK Eisfeld","year":"2017","unstructured":"Eisfeld AK, Mr\u00f3zek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211\u20138.","journal-title":"Leukemia"},{"key":"1069_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12301","volume":"161","author":"EP Nacheva","year":"2013","unstructured":"Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, et al. Does BCR\/ABL1 positive acute myeloid leukaemia exist? Br J Haematol. 2013;161:541\u201350.","journal-title":"Br J Haematol"},{"key":"1069_CR10","doi-asserted-by":"publisher","first-page":"15441","DOI":"10.3390\/ijms242015441","volume":"24","author":"L Boucher","year":"2023","unstructured":"Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz MP, et al. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis. Int J Mol Sci. 2023;24:15441.","journal-title":"Int J Mol Sci"},{"key":"1069_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1069_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00712-7","volume":"12","author":"F Vergez","year":"2022","unstructured":"Vergez F, Largeaud L, Bertoli S, Nicolau ML, Rieu JB, Vergnolle I, et al. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. Blood Cancer J. 2022;12:117.","journal-title":"Blood Cancer J"},{"key":"1069_CR13","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimawade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"1069_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","volume":"127","author":"CP Soupir","year":"2007","unstructured":"Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127:642\u201350.","journal-title":"Am J Clin Pathol"},{"key":"1069_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.107002","volume":"124","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Zhao D, Eladl E, Capo-Chichi JM, Kim DDH, Chang H. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. Leuk Res. 2023;124:107002.","journal-title":"Leuk Res"},{"key":"1069_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41375-023-02068-8","volume":"38","author":"M Ozga","year":"2024","unstructured":"Ozga M, Nicolet D, Mr\u00f3zek K, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024;38:45\u201357.","journal-title":"Leukemia"},{"key":"1069_CR17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.bbmt.2018.04.020","volume":"24","author":"GJ Min","year":"2018","unstructured":"Min GJ, Kim H-J, Yoon J-H, Kwak D-H, Park S-S, Jeon Y-W, et al. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome\u2013Positive Acute Myeloid Leukemia in Adults. Biol Blood Marrow Transplant. 2018;24:1621\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1069_CR18","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/bmt.2015.206","volume":"50","author":"SP Chantepie","year":"2015","unstructured":"Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, et al. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. Bone Marrow Transpl. 2015;50:1586\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1069_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ajh.24928","volume":"93","author":"VL Lazarevic","year":"2018","unstructured":"Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, et al. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2018;93:31\u201339.","journal-title":"Am J Hematol"},{"key":"1069_CR20","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1200\/JCO.19.00416","volume":"37","author":"L Angenendt","year":"2019","unstructured":"Angenendt L, R\u00f6llig C, Montesinos P, Martinez-Cuadron D, Barragan E, Garcia R, et al. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019;37:2632\u201342.","journal-title":"J Clin Oncol"},{"key":"1069_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/bloodadvances.2018015594","volume":"2","author":"NR Neuendorff","year":"2018","unstructured":"Neuendorff NR, Hemmati P, Arnold R, Ihlow J, D\u00f6rken B, M\u00fcller-Tidow C, et al. BCR-ABL(+) acute myeloid leukemia: are we always dealing with a high-risk disease? Blood Adv. 2018;2:1409\u201311.","journal-title":"Blood Adv"},{"key":"1069_CR22","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","volume":"9","author":"M Copland","year":"2022","unstructured":"Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial. Lancet Haematol. 2022;9:e121\u201332.","journal-title":"Lancet Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01069-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01069-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01069-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T05:10:24Z","timestamp":1717132224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01069-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01069-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4205555\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SB declares a consulting or advisory role with Abbvie, Astellas, BMS-Celgene, Jazz Pharmaceuticals as well as Servier and received travel grants from Abbvie and Pfizer. CR declares a consulting or advisory role with Abbvie, Amgen, Astellas, BMS, Boehringer, Jazz Pharmaceuticals as well as Servier, received research funding from Abbvie, Amgen, Astellas, BMS, Iqvia and Jazz Pharmaceuticals, and support for attending meetings and\/or travel from Abbvie, Novartis and Servier. AP declares a consulting or advisory role with Astellas, BMS, Servier, Abbvie, Gilead, Jazz Pharmaceuticals, Novartis, Pfizer, received research funding from Astellas, BMS, Roche, Servier and support for attending meetings and\/or travel from Servier, Abbvie. FV: research grants from Pierre Fabre and Roche; advisor for Astellas and Amgen. FH: consultancy Novartis, Pfizer, Incyte, honoraria Amgen, Servier; Isabelle Luquet: advisory role for Jazz Pharmaceuticals. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The cohort has been approved by the national ethical authorities (CCTIRS (ref 15.319) and CNIL (ref 915285)). All patients included in the DATAML cohort received and signed the information notice to express their non-opposition for the use of their data for research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"91"}}